Drug intelligence / Profile preview

Manpenkang

Development stage: Phase 3
Lead developer: Shaanxi Jingwei Group
Modality: Small Molecules
Administration: Rectal

Overview

Manpenkang is a Traditional Chinese Medicine (TCM) formulation developed by Shaanxi Jingwei Group Co., Ltd. for the treatment of chronic pelvic pain and sequelae of pelvic inflammatory disease (PID). It is specifically designed to address the TCM syndrome of damp-heat and blood stasis (湿热瘀毒蕴结证). The drug is formulated as an enema solution, allowing for rectal administration to facilitate local absorption and therapeutic action within the pelvic cavity. Clinical evaluation, including the Phase III trial CTR20140224 in China, has focused on assessing its safety and efficacy in alleviating chronic pelvic symptoms compared to placebo.

Brand names: Manpenkang
Other names: Manpenkang enemaManpenkang Guanchangye

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Manpenkang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manpenkang.